These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 11488556)

  • 1. Gender-based differences in the toxicity of pharmaceuticals--the Food and Drug Administration's perspective.
    Miller MA
    Int J Toxicol; 2001; 20(3):149-52. PubMed ID: 11488556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Male/female differences in pharmacology: safety issues with QT-prolonging drugs.
    Anthony M
    J Womens Health (Larchmt); 2005; 14(1):47-52. PubMed ID: 15692277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Food and Drug Administration Office of Women's Health: impact of science on regulatory policy.
    Obias-Manno D; Scott PE; Kaczmarczyk J; Miller M; Pinnow E; Lee-Bishop L; Jones-London M; Chapman K; Kallgren D; Uhl K
    J Womens Health (Larchmt); 2007; 16(6):807-17. PubMed ID: 17678451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
    Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
    Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part I.
    Anthony M; Berg MJ
    J Womens Health Gend Based Med; 2002 Sep; 11(7):601-15. PubMed ID: 12396893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Female gender does not influence the magnitude of ibutilide-induced repolarization delay and incidence of torsades de pointes in an in vivo rabbit model of the acquired long QT syndrome.
    Johansson M; Carlsson L
    J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):247-54. PubMed ID: 11584331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs for men and women - how important is gender as a risk factor for TdP?
    Coker SJ
    Pharmacol Ther; 2008 Aug; 119(2):186-94. PubMed ID: 18472167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. US Food and Drug Administration office of women's health: update.
    Sheppard A
    J Am Med Womens Assoc (1972); 1999; 54(2):97-8. PubMed ID: 10319599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inside the black box: current policies and concerns with the United States Food and Drug Administration's highest drug safety warning system.
    Halloran K; Barash PG
    Curr Opin Anaesthesiol; 2010 Jun; 23(3):423-7. PubMed ID: 20446348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender differences in the proarrhythmic potential of QT-prolonging drugs.
    Wolbrette D
    Curr Womens Health Rep; 2002 Apr; 2(2):105-9. PubMed ID: 12116598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
    Pearson EC; Woosley RL
    Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):747-53. PubMed ID: 15918160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse drug reactions in women's health care.
    Tharpe N
    J Midwifery Womens Health; 2011; 56(3):205-13. PubMed ID: 21535369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.
    Wysowski DK; Corken A; Gallo-Torres H; Talarico L; Rodriguez EM
    Am J Gastroenterol; 2001 Jun; 96(6):1698-703. PubMed ID: 11419817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. News from the Society for Women's Health Research: FDA doing poor job of monitoring drugs for sex differences.
    Greenberger P
    J Womens Health Gend Based Med; 2001 Nov; 10(9):829-30. PubMed ID: 11747675
    [No Abstract]   [Full Text] [Related]  

  • 15. Droperidol, QT prolongation, and sudden death: what is the evidence?
    Kao LW; Kirk MA; Evers SJ; Rosenfeld SH
    Ann Emerg Med; 2003 Apr; 41(4):546-58. PubMed ID: 12658255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gender-related differences in pharmacokinetics and pharmacodynamics].
    Thürmann PA
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 May; 48(5):536-40. PubMed ID: 15887063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?
    Meyer-Massetti C; Cheng CM; Sharpe BA; Meier CR; Guglielmo BJ
    J Hosp Med; 2010 Apr; 5(4):E8-16. PubMed ID: 20394022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Participation of women in clinical trials for new drugs approved by the food and drug administration in 2000-2002.
    Yang Y; Carlin AS; Faustino PJ; Motta MI; Hamad ML; He R; Watanuki Y; Pinnow EE; Khan MA
    J Womens Health (Larchmt); 2009 Mar; 18(3):303-10. PubMed ID: 19243271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of high-risk use of QT-prolonging medications.
    Allen LaPointe NM; Curtis LH; Chan KA; Kramer JM; Lafata JE; Gurwitz JH; Raebel MA; Platt R
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):361-8. PubMed ID: 16178046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
    Singh BN; Wadhani N
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.